SK Biopharmaceuticals Co., Ltd.
326030
Rank in Stocks
#3973
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Share Price
$52.21
Market Cap
$4.09B
Change (1 day)
1.34%
Change (1 year)
-30.21%
Country
KR
Trade SK Biopharmaceuticals Co., Ltd. (326030)
Category
Healthcare
Stock split history for SK Biopharmaceuticals Co., Ltd. (326030)
SK Biopharmaceuticals Co., Ltd. stock (symbol: 326030) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One 326030 share bought prior to Oct 21, 2026 would equal to 0 326030 shares today.
The most recent stock split occurred on Oct 21, 2026.
One 326030 share bought prior to Oct 21, 2026 would equal to 0 326030 shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
